Sandu Pharmaceuticals Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company reported a profit of ₹78.52 lakh for the quarter, a notable increase compared to the previous periods. The results were discussed and approved by the Board of Directors on November 14, 2026. These results are prepared in compliance with Ind-AS standards.
Sandu Pharmaceuticals Announces Q2 FY27 Results
Sandu Pharmaceuticals Limited has officially released its unaudited standalone financial results for the quarter and half year ended September 30, 2026. The Board of Directors convened on Saturday, November 14, 2026, to discuss and approve these financial statements.
Financial Highlights
For the quarter ended September 30, 2026, Sandu Pharmaceuticals reported a profit of ₹78.52 lakh. This figure represents the profit after tax. The company’s total income for the same quarter was ₹1951.59 lakh. The expenses incurred for the quarter amounted to ₹1865.67 lakh.
Looking at the half-yearly performance, the profit for the period ended September 30, 2026, stood at ₹101.35 lakh. Total income for the half-year was ₹3592.20 lakh, with total expenses recorded at ₹3470.24 lakh.
The Unaudited Financial Results and the Limited Review Report are available on the company’s website, www.sandu.in.
Audit and Review
The financial results were prepared in compliance with Ind-AS and were subjected to a limited review by M/s Dave & Dave Chartered Accountants, Mumbai. The audited figures for the quarter represent balancing figures between the full financial year audited figures and the published year-to-date figures up to six months ended of the respective financial year. Figures for previous periods have been reclassified or regrouped where necessary.
Source: BSE
